Updated on 8 November 2013
Allied is expecting significant growth in Group earnings over the coming 12 months to 3 years as it continues to grow revenue from its infusion product portfolio and its regenerative tissue programs.
The Company also has plans to expand its regenerative tissue portfolio with additional tissue products for cardiovascular repair and reconstruction, vessel repair and conduits; as well as other applications like cellular therapies, hernia and pelvic floor repair.
Allied also continues to progress well with its 510(K) application for CardioCel with the FDA. The Company anticipates US marketing approval in 2014.